8-K
filed June 18, 2026, 4:55 PM ET
ticker SUPN
CIK 0001356576
other
confidence high
sentiment neutral
materiality 0.15
Supernus shareholders approve all proposals, including equity plan share increase
SUPERNUS PHARMACEUTICALS, INC.
- Elected Class I directors Frederick M. Hudson (45.1M for) and Charles W. Newhall, III (41.7M for).
- Say-on-pay approved with 45.6M votes for, 1.7M against, 7.7K abstain.
- Ratified KPMG as auditor for FY2026 (49.9M for, 417K against).
- Amendment to 2021 Equity Incentive Plan to increase shares available passed (41.9M for, 5.3M against).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
SUPERNUS PHARMACEUTICALS, INC. shareholders approved To approve, on a non-binding basis, the compensation paid to our named executive officers. at the 2026-06-18 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-18
Exact text from the filing
Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers. Votes For Votes Against Abstain Broker Non-Votes 45,552,633 1,675,355 7,714 3,073,181
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
SUPERNUS PHARMACEUTICALS, INC. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-18 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-18
Exact text from the filing
Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Abstain Broker Non-Votes 49,882,228 417,336 9,319 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
SUPERNUS PHARMACEUTICALS, INC. shareholders approved To act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the number of shares available under the Plan. at the 2026-06-18 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-06-18
Exact text from the filing
Proposal 4: To act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the "Plan") to increase the number of shares available under the Plan. Votes For Votes Against Abstain Broker Non-Votes 41,925,692 5,302,088 7,922 3,073,181
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
SUPERNUS PHARMACEUTICALS, INC. shareholders approved Election of Class I Directors at the 2026-06-18 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-18
Exact text from the filing
Proposal 1: Election of Class I Directors, each to serve until the Annual Meeting of the Company in 2029. Name Votes For Votes Withheld Broker Non-Votes Frederick M. Hudson 45,058,634 2,177,068 3,073,181 Charles W. Newhall, III 41,743,154 5,492,548 3,073,181
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.